Press release
Lewy Body Dementia Market to Reach USD 9.4 Billion by 2034
Lewy Body Dementia
Download Full PDF Sample Copy of Market Report @ https://exactitudeconsultancy.com/request-sample/71909
With aging populations and rising awareness, the LBD market is expanding. Current management relies on cholinesterase inhibitors, antipsychotics, Parkinson's medications, and supportive care, but safety concerns and limited efficacy create an urgent need for new therapies. Advances in neuroimaging, biomarker testing, and digital health monitoring are reshaping early detection and management.
Market Overview
• Market Size (2024): USD 5.2 billion
• Forecast (2034): USD 9.4 billion
• CAGR (2025-2034): 6.0%
Growth is driven by rising dementia prevalence, improved diagnosis, and pipeline therapies targeting alpha-synuclein and neuroinflammation.
Key Highlights:
• LBD affects ~1.4 million people in the U.S. alone, with millions more worldwide.
• Early misdiagnosis as Alzheimer's or Parkinson's remains common.
• Cholinesterase inhibitors (donepezil, rivastigmine) are widely prescribed.
• Digital biomarkers and AI-powered neurocognitive testing gaining adoption.
Segmentation Analysis
By Product Type:
• Pharmacological Therapies
o Cholinesterase Inhibitors (Donepezil, Rivastigmine, Galantamine)
o Parkinsonian Agents (Levodopa, Carbidopa)
o Antipsychotics (Quetiapine, Clozapine - cautious use due to sensitivity)
o Antidepressants (SSRIs, SNRIs for mood symptoms)
o Pipeline Therapies (alpha-synuclein antibodies, neuroprotective drugs)
• Non-Pharmacological Interventions
o Cognitive Behavioral Therapy (CBT)
o Physical & Occupational Therapy
o Lifestyle and Supportive Care Programs
• Diagnostics & Digital Tools
o PET & MRI Imaging
o CSF and Blood Biomarkers
o Digital Cognitive Assessment Tools
By Platform:
• Small Molecules (cholinesterase inhibitors, antipsychotics)
• Biologics (immunotherapies under research)
• Digital Health Tools
By Technology:
• AI-Powered Neurocognitive Testing
• Biomarker-Based Diagnostics
• Digital Therapeutics & Remote Monitoring
By End Use:
• Hospitals & Neurology Clinics
• Memory Care Centers
• Home Care Settings
• Research Institutes
By Application:
• Early-Stage Lewy Body Dementia
• Moderate-to-Severe LBD
• Clinical Research
Segmentation Summary:
Pharmacological therapies dominate, but digital and biomarker-based diagnostics are rapidly growing. Pipeline biologics targeting alpha-synuclein aggregation represent future breakthroughs.
Explore Full Report here: https://exactitudeconsultancy.com/reports/71909/lewy-body-dementia-market
Regional Analysis
North America
• ~44% share in 2024.
• Strong diagnostic adoption, advanced dementia care infrastructure.
• FDA approvals of symptomatic therapies and biomarker-driven research.
Europe
• ~29% share.
• Germany, UK, and France lead in dementia research and integrated care models.
• EMA fostering innovation in neurodegenerative drug pipelines.
Asia-Pacific
• Fastest-growing region with CAGR of ~7.2%.
• Rising dementia burden in Japan, China, and India.
• Expanding memory clinics and digital health adoption.
Middle East & Africa
• Smaller market but growing with aging demographics.
• Limited specialized dementia infrastructure.
Latin America
• Brazil and Mexico driving demand.
• Increasing access to generics and caregiver support programs.
Regional Summary:
North America and Europe dominate due to infrastructure and R&D pipelines, while Asia-Pacific grows fastest due to rapid demographic aging and healthcare expansion.
Market Dynamics
Key Growth Drivers:
• Rising global dementia prevalence.
• Improved diagnosis with biomarkers and imaging.
• Pipeline therapies targeting alpha-synuclein and neuroinflammation.
• Digital health solutions for remote cognitive monitoring.
Key Challenges:
• Misdiagnosis with Alzheimer's and Parkinson's disease.
• Lack of disease-modifying therapies.
• High care costs and caregiver burden.
• Limited access in low-income regions.
Latest Trends:
• Alpha-synuclein immunotherapies under clinical trials.
• AI-based cognitive assessments for early detection.
• Growth of digital therapeutics and caregiver support apps.
• Integration of multi-modal care: drug + therapy + digital health.
Get Your Exclusive Offer with up to 10% Discount : https://exactitudeconsultancy.com/checkout/?currency=USD&type=single_user_license&report_id=71909
Competitor Analysis
Major Players in the Market:
• Novartis AG (Rivastigmine)
• Eisai Co., Ltd. (Donepezil - with Pfizer Inc.)
• Johnson & Johnson
• GlaxoSmithKline plc
• Eli Lilly and Company (neurodegenerative pipeline)
• Biogen Inc. (anti-amyloid and alpha-synuclein R&D)
• Roche Holding AG (diagnostics & biomarkers)
• AbbVie Inc.
• Otsuka Pharmaceutical Co., Ltd.
• Cogstate Ltd. (digital cognitive testing tools)
Competitive Summary:
Novartis and Eisai dominate symptomatic therapy, while Biogen, Roche, and Eli Lilly lead neurodegenerative R&D. Cogstate and digital health firms pioneer neurocognitive testing. Competition centers on pipeline biologics, AI diagnostics, and integrated dementia care models.
Conclusion
The Lewy Body Dementia (LBD) Market, valued at USD 5.2 billion in 2024, is projected to reach USD 9.4 billion by 2034, growing at a CAGR of 6.0%. Expanding diagnosis, digital health adoption, and pipeline therapies will continue to shape the market.
Key Takeaways:
• Cholinesterase inhibitors remain standard of care, but biologics are emerging.
• North America and Europe dominate, while Asia-Pacific grows fastest.
• AI-based cognitive diagnostics and digital therapeutics gaining traction.
• Integrated multimodal care will define future LBD management.
The next decade will transform LBD care from symptom-focused management to precision-driven, biomarker-guided, and digitally integrated dementia care, creating opportunities for pharma, biotech, and digital health innovators.
This report is also available in the following languages : Japanese (レビー小体型認知症市場), Korean (루이소체 치매 시장), Chinese (路易体痴呆症市场), French (Marché de la démence à corps de Lewy), German (Markt für Lewy-Body-Demenz), and Italian (Mercato della demenza da corpi di Lewy), etc.
Request for a sample of this research report at (Use Corporate Mail ID for Quick Response) @ https://exactitudeconsultancy.com/reports/71909/lewy-body-dementia-market#request-a-sample
Our More Reports:
Single Nucleotide Polymorphism (SNP) Genotyping Market
https://exactitudeconsultancy.com/reports/72390/single-nucleotide-polymorphism-snp-genotyping-market
Digital Psychotherapeutics Market
https://exactitudeconsultancy.com/reports/72389/digital-psychotherapeutics-market
Whole Genome Sequencing Market
https://exactitudeconsultancy.com/reports/72388/whole-genome-sequencing-market
About Us
Exactitude Consultancy is a market research & consulting services firm which helps its client to address their most pressing strategic and business challenges. Our market research helps clients to address critical business challenges and also helps make optimized business decisions with our fact-based research insights, market intelligence, and accurate data.
https://bulletin.exactitudeconsultancy.com/
https://www.thehealthanalytics.com/
https://www.analytica.global/
https://www.marketintelligencedata.com/
https://www.marketinsightsreports.com/
https://exactitudeconsultancy.com/
Connect Us:
Irfan Tamboli
PHONE NUMBER +1 (704) 266-3234
EMAIL ADDRESS: sales@exactitudeconsultancy.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Lewy Body Dementia Market to Reach USD 9.4 Billion by 2034 here
News-ID: 4179609 • Views: …
More Releases from Exactitude Consultancy
Cold Planer Market Sees Consistent Growth Supported by Global Road Rehabilitatio …
The global cold planer market is experiencing steady growth as governments and private contractors increase spending on road rehabilitation, resurfacing, and infrastructure modernization. Cold planers, also known as milling machines, are widely used to remove damaged asphalt and concrete surfaces efficiently, supporting sustainable road construction practices.
Download Full PDF Sample Copy of Market Report @ https://exactitudeconsultancy.com/request-sample/68250
Key Market Highlights
• Increasing focus on road maintenance and resurfacing projects
• Growing demand for efficient and precision milling…
Credit Management Software Market Accelerates as Organizations Focus on Risk Mit …
The global credit management software market is witnessing robust growth as organizations across industries adopt digital solutions to manage credit risk, improve receivables performance, and strengthen financial controls. Credit management software enables businesses to automate credit scoring, monitor customer creditworthiness, and streamline collections processes.
Download Full PDF Sample Copy of Market Report @ https://exactitudeconsultancy.com/request-sample/68248
Key Market Highlights
• Growing adoption of automated credit risk assessment tools
• Increasing focus on working capital and cash flow management
• Integration…
Session Border Controller Market Expands Rapidly as Enterprises and Telecom Oper …
The global session border controller (SBC) market is experiencing strong growth as telecom operators and enterprises increasingly deploy SBC solutions to secure, manage, and optimize real-time IP communications. SBCs play a critical role in protecting voice over IP (VoIP), unified communications (UC), and multimedia sessions from cyber threats while ensuring interoperability and quality of service.
Download Full PDF Sample Copy of Market Report @ https://exactitudeconsultancy.com/request-sample/68246
Key Market Highlights
• Growing adoption of VoIP and…
Biofuel Market Including E-Methane and Sustainable Aviation Fuel Gains Strong Tr …
The global biofuel market, encompassing e-methane, sustainable aviation fuel (SAF), and other advanced biofuels, is witnessing robust growth as governments and industries intensify efforts to reduce carbon emissions and transition toward cleaner energy sources. These fuels play a critical role in achieving net-zero targets while enabling decarbonization of hard-to-abate sectors such as aviation, shipping, and heavy transportation.
Download Full PDF Sample Copy of Market Report @ https://exactitudeconsultancy.com/request-sample/68244
Key Market Highlights
• Rapid growth of…
More Releases for Lewy
Lewy Body Dementia (LBD) Market to Reach USD 5.12 Billion by 2034
Pune, India - December 2025 - The global Lewy Body Dementia (LBD) Market, valued at USD 2.98 billion in 2024, is projected to reach USD 5.12 billion by 2034, growing at a 5.6% CAGR (2025-2034), according to Exactitude Consultancy. Rising neurodegenerative disease prevalence, improved diagnostic imaging, and growing awareness of cognitive and behavioral symptoms are driving market expansion.
Download Full PDF Sample Copy of Market Report @ https://exactitudeconsultancy.com/request-sample/71909
Market Summary
The Lewy Body…
Lewy Body Dementia Treatment Market Trends That Will Shape the Next Decade: Insi …
Use code ONLINE20 to get 20% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
How Large Will the Lewy Body Dementia Treatment Market Size By 2025?
The market for lewy body dementia therapies has experienced robust expansion lately, projected to increase its valuation from $4.43 billion in 2024 to $4.69 billion in 2025, reflecting a compound annual growth rate (CAGR) of 5.8%; this…
Lewy Body Dementia Market Forecast 2025-2034: Comprehensive Analysis And Growth …
We've updated all our reports with current data on tariff changes, trade developments, and supply chain shifts affecting key industries.
What Is the Projected Growth of the Lewy Body Dementia Market?
In recent times, the market size for Lewy body dementia has witnessed substantial growth. It is projected to increase from $1.12 billion in 2024 to $1.21 billion in 2025, with a compound annual growth rate (CAGR) of 7.5%. The historic growth…
Lewy Body Dementia Treatment Market Challenges: Growth, Share, Value, Trends and …
Lewy Body Dementia Treatment Market Size And Forecast by 2031
The LBD Therapy Market is expanding rapidly, driven by increasing consumer demand, technological advancements, and industry-wide innovation. According to top market research firms, businesses in the Neurodegenerative Disorder Treatment Market are prioritizing digital transformation, product development, and data-driven decision-making to stay competitive. With rising investments in automation and efficiency, the Dementia Care Market is evolving to meet changing customer preferences.…
Lewy Body Dementia Treatment Market Focuses on Advancements in Diagnosis and The …
Global Lewy Body Dementia Treatment Market, By Drug Type (Cholinesterase Inhibitors, Antipsychotic Drugs, Antidepressants, Benzodiazepine, and Modafinil), Application Type (Parkinson's Disease and Alzheimer's Disease), Mode of Purchase (Prescription and Over the Counter), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies and Others) - Industry Trends and Forecast to 2031.
Data Bridge Market Research analyses that the Global Lewy Body Dementia Treatment Market which was USD 5.66 Billion in 2023…
Lewy Body Dementia Treatment Market to see Rapid Growth by 2029
The Lewy Body Dementia Treatment Market size is expected to grow at an annual average of CAGR 4% during the forecast period (2023-2029). Lewy Body Dementia (LBD) affects people mostly aged 50 years and above. It accounts for about 1-2% of all the cases of dementia. Lewy body is also projected to be found in other neurological disorders such as Parkinson's disease and Alzheimer's disease. Furthermore, underdiagnosis and late…
